Skip to main content

What the FDA labels say about taking them together

Finasteride and testosterone

Finasteride's FDA label of March 18, 2026 names testosterone in its contraindications section; the testosterone labels PlainMeds reads (4) do not name finasteride.

Check it at the source: the finasteride FDA label on DailyMed (effective March 18, 2026, Organon LLC); the testosterone FDA label on DailyMed (effective July 25, 2025, Azurity Pharmaceuticals, Inc.).

What does the finasteride label say about testosterone?

Finasteride label, contraindications

Because of the ability of Type II 5α-reductase inhibitors to inhibit the conversion of testosterone to 5α-dihydrotestosterone (DHT), finasteride may cause abnormalities of the external genitalia of a male fetus of a pregnant female who receives finasteride.

Source: FDA drug label (Propecia, NDA020788), Organon LLC, effective October 14, 2024 (SPL set 6f904709-65aa-44ce-b144-b4c8a0416e36), via openFDA

Source: FDA drug label (PROSCAR), Organon LLC, effective March 18, 2026 (SPL set 6f988153-fc74-4ca4-b29a-111f750c4a4b), via openFDA; the full label on DailyMed

What does the testosterone label say about finasteride?

Testosterone's label (effective July 25, 2025) and its 3 other brand-application labels do not name finasteride in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (AZMIRO), Azurity Pharmaceuticals, Inc., effective July 25, 2025 (SPL set 235b5625-570d-3fba-e063-6394a90aa2d1), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

30Finasteride generic labelers
33Testosterone generic labelers
FinasterideTestosterone
Labeled forEnlarged prostate (BPH)Breast cancer
Boxed warningNoNo
Pharmacy cost (NADAC)$0.0688 per tablet 5 mg tablet$11.39 per mL 200 mg/mL
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?